Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The Impact of Donor Type on Long-Term Health Status and Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Leucemie de l'Enfant et de L'Adolescent Study

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Service de pédiatrie multidisciplinaire Hôpital de la Timone Enfants - APHM; Hôpital de la Timone CHU - APHM (TIMONE); Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants (SPMC); Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM); Hématologie et immunologie pédiatrique; Hospices Civils de Lyon (HCL)-CHU Lyon-Institut d'hématologie et d'oncologie pédiatrique CHU - HCL (IHOPe); Hospices Civils de Lyon (HCL)-Hôpital Femme-Mère-Enfant (HFME); Service d'hématologie et immunologie pédiatrique; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7); CHU Trousseau APHP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Centre de référence des maladies héréditaires du métabolisme (MaMEA Nancy-Brabois); Groupe hospitalier Pellegrin; Service de Pédiatrie, Unité d'Oncologie et Hématologie Pédiatrique; Centre Hospitalier Universitaire de Nice (CHU Nice); Institut de Génétique et Développement de Rennes (IGDR); Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ); Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Hématogoie pédiatrique; hôpital Sud; Service d'oncologie médicale CHU Strasbourg; Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg); Les Hôpitaux Universitaires de Strasbourg (HUS)-Les Hôpitaux Universitaires de Strasbourg (HUS); Service d'hématologie pédiatrique; CHU Clermont-Ferrand-CIC Inserm 501; Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE); Service de pédiatrie spécialisée et médecine infantile (neurologie, pneumologie, maladies héréditaires du métabolisme) Hôpital de la Timone - APHM; Centre Hospitalier Universitaire d'Angers (CHU Angers); PRES Université Nantes Angers Le Mans (UNAM); Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Hôpital Robert Debré Paris; Hôpital Robert Debré; Pédiatrie et oncologie pédiatrique Hôpital de la Timone - APHM; Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE); the French National Clinical Research Program (grant no. PHRC10-24-02); French National Cancer Institute (InCA); French National Research Agency (ANR) 2011-043; Canceropole PACA 2016-03; Regional Council PACA 2016-03; Herault and the Bouches-du-Rhone departmental comities of the Ligue Contre le Cancer; French Institute for Public Health Research (IRESP)
    • بيانات النشر:
      HAL CCSD
      Elsevier
    • الموضوع:
      2016
    • Collection:
      Université de Rennes 1: Publications scientifiques (HAL)
    • نبذة مختصرة :
      International audience ; We compared the long-term impact of donor type (sibling donor [SD] versus matched unrelated donor [MUD] or umbilical cord blood [UCB]) on late side effects and quality of life (QoL) in childhood acute leukemia survivors treated with hematopoietic stem cell transplantation. We included 314 patients who underwent transplantation from 1997 to 2012 and were enrolled in the multicenter French Leucemie de l'Enfant et de L'Adolescent ("Leukemia in Children and Adolescents") cohort. More than one-third of the patients were adults at last visit; mean follow-up duration was 6.2 years. At least 1 late effect was observed in 284 of 314 patients (90.4%). The average number of adverse late effects was 2.1 +/- 1, 2.4 +/- 2, and 2.4 +/- 2 after SD, MUD, and UCB transplantation, respectively. In a multivariate analysis, considering the SD group as the reference, we did not detect an impact of donor type for most sequelae, with the exception of increased risk of major growth failure after MUD transplantation (odds ratio [OR], 2.42) and elevated risk of osteonecrosis after UCB transplantation (OR, 4.15). The adults and children's parents reported comparable QoL among the 3 groups. Adult patient QoL scores were lower than age- and sex-matched French reference scores for almost all dimensions. We conclude that although these patients are heavily burdened by long-term complications, donor type had a very limited impact on their long-term health status and QoL.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/27522039; hal-01415935; https://univ-rennes.hal.science/hal-01415935; https://univ-rennes.hal.science/hal-01415935/document; https://univ-rennes.hal.science/hal-01415935/file/The%20Impact%20of%20Donor%20Type%20on%20Long-Term.pdf; PUBMED: 27522039
    • الرقم المعرف:
      10.1016/j.bbmt.2016.08.004
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.3B4D38D9